Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma

被引:27
|
作者
Tsuda, Y. [1 ]
Tsoi, K. [1 ]
Parry, M. C. [1 ]
Stevenson, J. D. [1 ]
Fujiwara, T. [1 ]
Sumathi, V [1 ]
Jeys, L. M. [1 ]
机构
[1] Royal Orthopaed Hosp, Dept Oncol, Birmingham, W Midlands, England
来源
BONE & JOINT JOURNAL | 2020年 / 102B卷 / 06期
关键词
HIGH-DOSE METHOTREXATE; NONMETASTATIC OSTEOSARCOMA; NEOADJUVANT CHEMOTHERAPY; HISTOLOGIC RESPONSE; OSTEOGENIC-SARCOMA; PROGNOSTIC-FACTORS; DELAYED SURGERY; EXTREMITIES; EURAMOS-1; CISPLATIN;
D O I
10.1302/0301-620X.102B6.BJJ-2019-1307.R1
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Aims To assess the correlation between the histological response to preoperative chemotherapy and event-free survival (EFS) or overall survival (OS) in patients with high-grade localized osteosarcoma. Methods Out of 625 patients aged <= 40 years treated for primary high-grade osteosarcoma between 1997 and 2016, 232 patients without clinically detectable metastases at the time of diagnosis and treated with preoperative high-dose methotrexate, adriamycin and cisplatin (MAP) chemotherapy and surgery were included. Associations of chemotherapy-induced necrosis in the resected specimen and EFS or OS were assessed using Cox model and the Pearson's correlation coefficients (r). Time-dependent receiver operating characteristic analysis was applied to determine the optimal cut-off value of chemotherapy-induced necrosis for EFS and OS. Results OS was 74% (95% confidence interval (CI) 67 to 79) at five years. Median chemotherapy- induced necrosis was 85% (interquartile range (KIR) 50% to 97%). In multivariate Cox model, chemotherapy-induced necrosis was significantly associated with EFS and OS (hazard ratio (HR) = 0.99 (95% CI 0.98 to 0.99); p < 0.001 and HR = 0.98 (95% CI 0.97 to 0.99); p < 0.001, respectively). Positive correlation was observed between chemotherapy-induced necrosis and five-year EFS and five-year OS (r = 0.91; p < 0.001, and r = 0.85; p < 0.001, respectively). The optimal cut-off value of chemotherapy-induced necrosis for five-year EFS and five-year OS was 85% and 72%, respectively. Conclusion Chemotherapy-induced necrosis in the resected specimen showed positive correlation with EFS and OS in patients with high-grade localized osteosarcoma after MAP chemotherapy. In our analysis, optimal cut-off values of MAP chemotherapy-induced necrosis in EFS and OS were lower than the commonly used 90%, suggesting the need for re-evaluation of the optimal cut-off value through larger, international collaborative research.
引用
收藏
页码:795 / 803
页数:9
相关论文
共 50 条
  • [21] Analysis of Chemotherapy Dosage and Dosage Intensity and Survival Outcomes of High-Grade Osteosarcoma Patients Younger Than 40 Years
    Sun, Lingling
    Li, Yingjun
    Li, Hengyuan
    Zhang, Jian
    Li, Binghao
    Ye, Zhaoming
    CLINICAL THERAPEUTICS, 2014, 36 (04) : 567 - 578
  • [22] Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer
    Piedimonte, Sabrina
    Kessous, Roy
    Laskov, Ido
    Abitbol, Jeremie
    Kogan, Liron
    Yasmeen, Amber
    Salvador, Shannon
    Lau, Susie
    Gotlieb, Walter H.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2020, 42 (11) : 1339 - 1345
  • [23] Survival in total preoperative verus perioperative chemotherapy for patients with metastatic high-grade appendiceal adenocarcinoma undergoing CRS/HIPEC
    Morgan, Ryan B.
    Yan, Allie
    Dhiman, Ankit
    Sood, Divya
    Ong, Cecilia T.
    Wu, Xiaoyang
    Shergill, Ardaman
    Polite, Blase N.
    Turaga, Kiran
    Eng, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [24] Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup
    Hauben, EI
    Weeden, S
    Pringle, J
    Van Marck, EA
    Hogendoorn, PCW
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (09) : 1218 - 1225
  • [25] Surgical factors do not impact survival in high-grade serous ovarian carcinoma patients treated with neoadjuvant chemotherapy
    Stewart, J. M.
    Tone, A. A.
    Bernardini, M. Q.
    Ferguson, S. E.
    Dodge, J.
    Laframboise, S.
    Murphy, K. J.
    Rosen, B. P.
    May, T.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 43 - 43
  • [26] Impact of neoadjuvant chemotherapy duration on the survival of patients with advanced stage high-grade serous or endometrioid ovarian carcinoma
    Nasioudis, Dimitrios
    Ko, Emily
    Haggerty, Ashley
    Cory, Lori
    Giuntoli, Robert
    Kim, Sarah
    Simpkins, Fiona
    Morgan, Mark
    Latif, Nawar
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S183 - S184
  • [27] Evaluation of chemotherapy-induced nausea and vomiting in pediatric patients with high-grade glioma treated with lomustine-a case series
    Schellekens, Kim P. J.
    Hageman, Sarah Babette
    Haverkate, Els C.
    van de Wetering, Marianne D.
    Engels, Frederike K.
    Brinksma, Aeltsje
    de Vos-Kerkhof, Evelien
    SUPPORTIVE CARE IN CANCER, 2024, 32 (05)
  • [28] FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma
    Mikhaeel, NG
    Hutchings, M
    Fields, PA
    O'Doherty, MJ
    Timothy, AR
    ANNALS OF ONCOLOGY, 2005, 16 (09) : 1514 - 1523
  • [29] Survival in Total Preoperative vs. Perioperative Chemotherapy for Patients with Metastatic High-Grade Appendiceal Adenocarcinoma Undergoing CRS/HIPEC
    Morgan, Ryan B.
    Yan, Allie
    Dhiman, Ankit
    Shergill, Ardaman
    Polite, Blase
    Turaga, Kiran K.
    Eng, Oliver S.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2022, 26 (12) : 2591 - 2594
  • [30] Survival in Total Preoperative vs. Perioperative Chemotherapy for Patients with Metastatic High-Grade Appendiceal Adenocarcinoma Undergoing CRS/HIPEC
    Ryan B. Morgan
    Allie Yan
    Ankit Dhiman
    Ardaman Shergill
    Blase Polite
    Kiran K. Turaga
    Oliver S. Eng
    Journal of Gastrointestinal Surgery, 2022, 26 : 2591 - 2594